US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
EP1137634B1
(de)
*
|
1998-12-07 |
2005-06-15 |
Schering Corporation |
Verfahren zur herstellung von azetidinonen
|
KR100833089B1
(ko)
*
|
2000-12-21 |
2008-05-29 |
사노피-아벤티스 도이칠란트 게엠베하 |
신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
|
BR0206654A
(pt)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Combinações de ativador(es) de receptor ativado por proliferação de peroxisoma (ppar) e inibidor(es) de absorção de esterol e tratamentos para indicações vasculares
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
CN1275949C
(zh)
|
2001-03-28 |
2006-09-20 |
先灵公司 |
2-吖丁啶酮中间体化合物的对映体选择性合成
|
ES2272776T3
(es)
*
|
2001-09-21 |
2007-05-01 |
Schering Corporation |
Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
CN1756756A
(zh)
*
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
ES2311806T3
(es)
|
2003-03-07 |
2009-02-16 |
Schering Corporation |
Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
AU2003259547A1
(en)
*
|
2003-07-31 |
2005-02-14 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
AU2003282384A1
(en)
|
2003-11-24 |
2005-06-08 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
DE602004029715D1
(de)
*
|
2003-12-23 |
2010-12-02 |
Astrazeneca Ab |
Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
JP4590417B2
(ja)
*
|
2004-01-16 |
2010-12-01 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Npc1l1(npc3)およびこのリガンドの同定方法
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
WO2006026273A2
(en)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
JP2007526251A
(ja)
*
|
2004-12-03 |
2007-09-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミベ多形体
|
US20060234996A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Itai Adin |
Novel crystalline form of ezetimibe and processes for the preparation thereof
|
KR20080021082A
(ko)
*
|
2005-06-20 |
2008-03-06 |
쉐링 코포레이션 |
히스타민 h3 길항제로서 유용한 피페리딘 유도체
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
BRPI0605934A2
(pt)
*
|
2005-09-08 |
2009-05-26 |
Teva Pharma |
processos para a preparação de ( 3r, 4s) - 4 - ( (4-benziloxi ) fenil ) - 1 - ( 4 - fluorofenil ) - 3 - ( (s) - 3 - ( 4 - fluorofenil ) - 3 - hidroxipropil) - 2 - azetidinona, um intermediário para a sìntese da ezetimiba
|
EP2332526A3
(de)
|
2005-10-21 |
2011-10-12 |
Novartis AG |
Kombination eines Renin-Inhibitors mit einem anti-dyslipidämischen Wirkstoff oder einem Wirkstoff gegen Adipositas
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
US20090227786A1
(en)
*
|
2005-12-22 |
2009-09-10 |
Ana Gavalda I Escude |
Processes for preparing intermediate compounds useful for the preparation of ezetimibe
|
EP1986489A2
(de)
|
2006-02-24 |
2008-11-05 |
Schering Corporation |
Npc1l1-orthologe
|
WO2007108007A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Unichem Laboratories Limited |
A process for the preparation of ezetimibe via a novel intermediate
|
CA2647902A1
(en)
*
|
2006-03-29 |
2007-12-21 |
Medichem S.A. |
Processes for preparing ezetimibe and intermediate compounds useful for the preparation thereof
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20080058305A1
(en)
*
|
2006-08-29 |
2008-03-06 |
Vinod Kumar Kansal |
Processes for the purification of (3R,4S)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one
|
CA2661404A1
(en)
*
|
2006-09-05 |
2008-03-13 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
WO2008032338A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Manne Satyanarayana Reddy |
Improved process for the preparation of ezetimibe and its intermediates
|
EP2086324A2
(de)
*
|
2006-11-02 |
2009-08-12 |
Merck & Co., Inc. |
Heterozyklisch substituierte cholesterinsenker
|
JP2010529148A
(ja)
*
|
2007-06-07 |
2010-08-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミブ製造のための還元方法
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
*
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
PL387331A1
(pl)
|
2009-02-24 |
2010-08-30 |
Instytut Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania aldehydowego związku beta-laktamowego, związek pośredni, sposób wytwarzania związku pośredniego oraz zastosowanie związku pośredniego
|
US9388440B2
(en)
|
2009-04-01 |
2016-07-12 |
Mylan Laboratories Limited |
Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
|
EP2566497B1
(de)
|
2010-05-04 |
2015-07-29 |
Codexis, Inc. |
Biokatalysatoren zur ezetimib-synthese
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
CN102477008B
(zh)
*
|
2010-11-22 |
2014-05-21 |
沈阳药科大学 |
依泽替米贝的合成方法
|
WO2012076030A1
(en)
*
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN103086938A
(zh)
*
|
2011-10-28 |
2013-05-08 |
沈阳药科大学 |
依泽替米贝的合成方法
|
CN102531986A
(zh)
*
|
2012-02-23 |
2012-07-04 |
苏州朗科生物技术有限公司 |
一种依替米贝的制备方法
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103044305A
(zh)
*
|
2013-01-24 |
2013-04-17 |
上海现代制药股份有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
CN104072398B
(zh)
*
|
2014-07-03 |
2016-02-03 |
河南省科学院化学研究所有限公司 |
一种合成依折麦布的方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN107033051A
(zh)
*
|
2017-06-08 |
2017-08-11 |
武汉励合生物医药科技有限公司 |
一种依泽替米贝的制备方法
|